Dianthus Therapeutics Closes Upsized $288 Million Public Offering to Advance Complement Therapeutics Pipeline
核心洞察
Dianthus Therapeutics successfully closed an upsized $288 million underwritten public offering, nearly doubling the initially proposed $150 million raise to fund its complement (搜索) therapeutics development.
The biotechnology company sold 7.6 million shares at $33.00 per share plus pre-funded warrants, with underwriters fully exercising their option to purchase additional shares.
Proceeds will advance the company's preclinical and clinical development activities for next-generation antibody complement (搜索) therapeutics targeting severe autoimmune diseases (搜索).
Dianthus Therapeutics successfully closed an upsized $288 million underwritten public offering on September 11, 2025, providing substantial funding to advance its pipeline of next-generation antibody complement (搜索) therapeutics for severe autoimmune diseases (搜索). The clinical-stage biotechnology company nearly doubled its initial fundraising target, demonstrating strong investor confidence in its complement-focused approach.
Offering Details and Market Response
The company sold 7,627,879 shares of common stock at $33.00 per share, with underwriters fully exercising their option to purchase an additional 1,140,000 shares. Additionally, Dianthus issued pre-funded warrants to purchase up to 1,112,121 shares at $32.999 per warrant to certain investors, with an exercise price of $0.001 per share and immediate exercisability.
The final offering size represented a significant increase from the initially proposed $150 million raise announced on September 8, 2025. The upsizing reflects strong institutional demand for the company's complement (搜索) therapeutics platform and development strategy.
Strategic Use of Proceeds
Dianthus intends to use the net proceeds to advance its preclinical and clinical development activities, as well as for working capital and general corporate purposes. The funding will support the continued development of claseprubart (搜索), the company's lead complement (搜索) therapeutic candidate, along with other compounds in its pipeline.
The company's forward-looking statements acknowledge potential risks in the development process, noting that "preclinical testing of claseprubart (搜索) and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials" and that development "may take longer and/or cost more than planned."
Company Platform and Focus
Dianthus Therapeutics is dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Massachusetts, the company comprises an experienced team of biotech and pharmaceutical executives leading the development of next-generation antibody complement (搜索) therapeutics.
The company's mission centers on delivering transformative medicines for people living with severe autoimmune and inflammatory diseases (搜索) through its complement (搜索)-targeted approach. This therapeutic strategy addresses a significant unmet medical need in the autoimmune disease space.
Investment Banking Syndicate
Jefferies (搜索), TD Cowen (搜索), Evercore ISI (搜索), and Stifel (搜索) served as joint book-running managers for the offering, while LifeSci Capital (搜索) acted as lead manager. The strong syndicate reflects the institutional interest in complement (搜索) therapeutics and Dianthus's specific approach to this therapeutic area.
The offering was conducted under a shelf registration statement that became effective on October 9, 2024, providing the company with flexibility in accessing capital markets to support its development programs.